Why Dyne Therapeutics Stock Was a Big Winner on Wednesday
Key Points
An analyst upgraded his recommendation on the biotech.
He now feels it's worthy of a buy, and what's more, he almost quadrupled his price target.
- 10 stocks we like better than Dyne Therapeutics ›
Dyne Therapeutics (NASDAQ: DYN) stock stood apart from its biotech peers on Hump Day, posting a meaty share price gain across the trading session. On the back of an analyst's upgrade, accompanied by a significant price target raise, investors piled into the stock to lift it to a nearly 7% increase.
A new bull in the pen
The person behind the upgrade was Jay Olson of Oppenheimer. Before market open, he changed his recommendation on Dyne stock to outperform (buy, in other words) from his previous perform (hold). He also nearly quadrupled his price target on the shares, to $40 apiece from $11.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
The exact reasoning for his move wasn't exactly clear. It doesn't seem coincidental that it came shortly after Dyne's latest report from the laboratory. On Monday, the company published a readout from a phase 1/2 clinical trial of its Duchenne muscular dystrophy (DMD) investigational drug zeleciment rostudirsen, which achieved both its primary and secondary endpoints.
Zeleciment rostudirsen was found to be efficacious in bolstering the production of a structural protein called dystrophin, which serves to protect muscles.
Big movements
Dyne is clearly eager to push the pipeline drug through the development process; it stated that it aims to submit it for accelerated U.S. Food and Drug Administration (FDA) approval in the second quarter of 2026 -- mere months away.
The company's stock has been a bit of a rollercoaster this week, with initial investor optimism souring on Tuesday after the company announced a relatively large secondary stock offering. I'd be bouncing along with the bulls, myself, as those trial results were impressive and suggest zeleciment rostudirsen might have a bright future when and if it hits pharmacy shelves.
Should you invest $1,000 in Dyne Therapeutics right now?
Before you buy stock in Dyne Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Dyne Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $521,550!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,133,904!*
Now, it’s worth noting Stock Advisor’s total average return is 981% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of December 8, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
